Description: Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
Home Page: www.organovo.com
0R02 Technical Analysis
11555 Sorrento Valley Road
San Diego,
CA
92121
United States
Phone:
858 224 1000
Officers
| Name | Title |
|---|---|
| Mr. Keith E. Murphy | Executive Chairman & Corporate Secretary |
| Mr. Thomas P. Hess CPA, MBA | President & CFO |
| Ms. Vaidehi Joshi | Director of Discovery Biology & Director |
| Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy & Business Development |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Energy |
|---|---|
| GIC Group: | Energy |
| GIC Industry: | Oil, Gas & Consumable Fuels |
| GIC Sub-Industry: | Coal & Consumable Fuels |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 244.5383 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 12 |